Aurinia Pharmaceuticals (AUPH) AI Stock Analysis

• Market Cap: $2.16B
• Dividend Yield: N/A
• Average Volume (3M): 1.87M
• Price to Earnings (P/E): 29.2
• Beta (1Y): 0.46
• Revenue Growth: 20.62%
• EPS Growth: N/A
• Country: US
• Employees: 130
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.23
• Shares Outstanding: 131,840,560
• 10 Day Avg. Volume: 1,790,268
• 30 Day Avg. Volume: 1,872,747
• PEG Ratio: -2.08
• Price to Book (P/B): 3.40
• Price to Sales (P/S): 5.46
• P/FCF Ratio: 29.13
• Enterprise Value/Market Cap: 0.57
• Enterprise Value/Revenue: 4.62
• Enterprise Value/Gross Profit: 5.21
• Enterprise Value/Ebitda: 12.00
• 1Y Price Target: $16.60
• Price Target Upside: 1.41% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 5
• EPS Forecast (FY): 0.78
• Revenue Forecast (FY): $279.14M

• Rating: 79 Outperform
• Price Target: $16.50 ▲(0.79% Upside)

Aurinia Pharmaceuticals' strong financial performance and positive earnings call are the most significant factors driving the stock's score. The company's robust revenue growth, profitability improvements, and promising clinical developments are key strengths. However, technical indicators suggest the stock may be overbought, and its high P/E ratio indicates a premium valuation, which could limit further upside.

Positive Factors

Revenue Growth

The strong growth in LUPKYNIS sales indicates robust demand and effective market penetration, supporting long-term revenue expansion and financial stability.

Cash Flow Generation

Significant improvement in cash flow generation enhances financial flexibility, enabling strategic investments and reducing reliance on external financing.

Clinical Developments

Progress in clinical developments for aritinercept suggests potential for future product diversification and revenue streams, strengthening the company's pipeline.

Negative Factors

Regulatory Challenges

Regulatory inquiries can lead to delays or additional compliance costs, impacting the company's ability to maintain product momentum and market confidence.

Legal Proceedings

Ongoing legal disputes may divert management attention and resources, potentially affecting strategic focus and operational efficiency.

Historical Volatility

Past financial volatility could signal underlying operational risks, potentially affecting future performance consistency and investor confidence.

Aurinia Pharmaceuticals Business Overview & Revenue Model

Company Description

Aurinia Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for autoimmune and kidney diseases. The company's primary product, LUPKYNIS (voclosporin), is an FDA-approved treatment for lupus nephritis, a serious and potentially life-threatening condition. Aurinia is committed to advancing medical science by conducting rigorous clinical trials and engaging with healthcare professionals to improve patient outcomes in underserved areas of medicine.

How the Company Makes Money

Aurinia Pharmaceuticals generates revenue primarily through the sale of its flagship product, LUPKYNIS, which is prescribed to patients with lupus nephritis. The company has established a revenue model that includes direct sales to healthcare providers, as well as potential partnerships and collaborations with pharmaceutical distributors and other stakeholders in the healthcare sector. Additionally, Aurinia may receive milestone payments and royalties from licensing agreements related to its product and technology. The company's financial performance can also be influenced by factors such as market demand for lupus nephritis treatments, reimbursement policies from insurance providers, and the overall competitive landscape in the biopharmaceutical industry.

Aurinia Pharmaceuticals Financial Statement Overview

Summary

Aurinia Pharmaceuticals demonstrates a strong financial recovery with significant improvements in revenue growth, profitability, and cash flow generation. The company has effectively managed its debt levels, and its return on equity has improved substantially. While historical volatility in financial metrics presents some risk, the current trajectory suggests a positive outlook for the company.

Income Statement

Aurinia Pharmaceuticals has shown strong revenue growth with a TTM (Trailing-Twelve-Months) increase of 2.19% and a significant improvement in profitability metrics. The gross profit margin is robust at 89.51%, and the net profit margin has improved to 23.31% from a low of -80.71% in 2022. EBIT and EBITDA margins have also turned positive, indicating improved operational efficiency. However, the company has experienced volatility in past years, which poses a risk.

Balance Sheet

The balance sheet reflects a stable financial position with a manageable debt-to-equity ratio of 0.24. Return on equity has improved significantly to 16.72%, showcasing effective use of equity to generate profits. The equity ratio is healthy, indicating a strong capital structure. However, the company has had periods of negative ROE in the past, which could indicate potential risks if not managed well.

Cash Flow

Aurinia Pharmaceuticals has shown a strong free cash flow growth rate of 29.75% in the TTM, indicating improved cash generation capabilities. The operating cash flow to net income ratio of 1.18 suggests efficient cash conversion. The free cash flow to net income ratio is nearly 1, indicating that the company is effectively converting its profits into cash. Past fluctuations in cash flow metrics highlight potential volatility.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	265.81M	235.13M	175.51M	134.03M	45.60M	50.12M
Gross Profit	236.06M	206.88M	161.37M	128.37M	44.51M	50.12M
EBITDA	102.42M	31.73M	-63.05M	-103.65M	-177.44M	-102.92M
Net Income	77.84M	5.75M	-78.02M	-108.18M	-180.97M	-102.68M
Balance Sheet
Total Assets	527.53M	550.64M	548.06M	470.86M	543.37M	463.66M
Cash, Cash Equivalents and Short-Term Investments	351.81M	358.48M	350.49M	389.39M	466.08M	398.33M
Total Debt	78.21M	79.37M	97.61M	8.09M	8.74M	8.41M
Total Liabilities	161.76M	173.17M	170.11M	65.42M	64.28M	55.91M
Stockholders Equity	365.77M	377.48M	377.95M	405.44M	479.09M	407.75M
Cash Flow
Free Cash Flow	119.87M	44.11M	-34.18M	-79.82M	-159.19M	-77.20M
Operating Cash Flow	120.10M	44.39M	-33.46M	-79.53M	-157.69M	-69.86M
Investing Cash Flow	43.21M	39.26M	-6.71M	-60.63M	-103.87M	-158.19M
Financing Cash Flow	-127.27M	-49.09M	-5.13M	2.43M	221.11M	194.38M

Aurinia Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 16.37
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AUPH, the sentiment is Positive. The current price of 16.37 is above the 20-day moving average (MA) of 14.91, above the 50-day MA of 13.11, and above the 200-day MA of 10.04, indicating a bullish trend. The MACD of 0.93 indicates Negative momentum. The RSI at 74.77 is Negative, neither overbought nor oversold. The STOCH value of 94.79 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AUPH.

Aurinia Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUPH	79 Outperform	$2.16B	29.17	20.65%	―	20.62%	―
IMCR	59 Neutral	$2.03B	―	-7.52%	―	27.51%	38.72%
MNKD	57 Neutral	$1.65B	57.05	―	―	17.44%	24.15%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
SRPT	49 Neutral	$2.20B	―	-21.37%	―	47.15%	-311.26%
BCRX	46 Neutral	$1.49B	―	―	―	45.38%	92.85%
CLDX	41 Neutral	$1.78B	―	-32.44%	―	-73.94%	-31.70%

Aurinia Pharmaceuticals Corporate Events

Aurinia Pharmaceuticals Reports Strong Q3 2025 Earnings

Aurinia Pharmaceuticals Inc. is a biopharmaceutical company focused on developing therapies for autoimmune diseases, notably introducing LUPKYNIS, the first FDA-approved oral therapy for lupus nephritis. In its latest earnings report, Aurinia Pharmaceuticals reported a significant increase in net income and product sales for the third quarter of 2025, driven by increased market penetration of LUPKYNIS. The company achieved net product sales of $70.6 million for the quarter, representing a 27% increase compared to the same period in 2024. Operating expenses decreased due to strategic restructuring efforts, leading to a substantial rise in income from operations. Aurinia’s cash position remains strong, with $351.8 million in cash, cash equivalents, and investments as of September 30, 2025, despite significant share repurchases. Looking forward, Aurinia’s management remains optimistic about continued growth and expansion in the autoimmune disease market, supported by ongoing development of new therapies.

Aurinia Pharma’s Earnings Call Highlights Growth and Challenges

Aurinia Pharmaceuticals’ recent earnings call reflected a generally positive sentiment, underscored by robust sales growth and strong financial performance, particularly for their flagship product, LUPKYNIS. The company also highlighted promising clinical advancements with aritinercept. However, potential challenges loom in the form of regulatory and legal issues.

Aurinia Pharmaceuticals Boosts 2025 Sales Guidance Amid Strong Q3 Performance

Aurinia Pharmaceuticals reported a significant increase in financial performance for the third quarter of 2025, with total revenue rising by 8% to $73.5 million. Notably, net product sales of LUPKYNIS grew by 27%, prompting the company to raise its sales guidance for 2025 to between $265 million and $270 million. The company also announced progress in advancing Aritinercept toward clinical studies for two autoimmune diseases, indicating a strategic focus on expanding its treatment portfolio.

The most recent analyst rating on (AUPH) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Aurinia Pharmaceuticals stock, see the AUPH Stock Forecast page.

Aurinia Pharmaceuticals Reports Strong Q3 2025 Growth and Raises Sales Guidance

Aurinia Pharmaceuticals reported significant financial growth for the third quarter of 2025, with LUPKYNIS sales increasing by 27% and total revenue reaching $73.5 million, an 8% rise from the previous year. The company has raised its 2025 sales guidance, reflecting strong momentum from updated lupus nephritis treatment guidelines and positive results from a Phase 1 study of aritinercept, which is advancing towards clinical studies in two autoimmune diseases.

The most recent analyst rating on (AUPH) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Aurinia Pharmaceuticals stock, see the AUPH Stock Forecast page.

Aurinia Pharmaceuticals to Announce Q3 2025 Financial Results and Business Update

Aurinia Pharmaceuticals announced it will report its financial results for the three and nine months ended September 30, 2025, and provide an update on its recent business progress on November 4, 2025. This announcement is significant as it may offer insights into the company’s financial health and strategic direction, potentially impacting its market positioning and stakeholder interests.

The most recent analyst rating on (AUPH) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Aurinia Pharmaceuticals stock, see the AUPH Stock Forecast page.

Aurinia Pharmaceuticals Advances Voclosporin Study in Young Lupus Nephritis Patients

Study Overview: Aurinia Pharmaceuticals is conducting a study titled An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis. The study aims to evaluate the long-term safety and tolerability of voclosporin over an additional 12 months in young patients who have completed previous treatment for lupus nephritis. This research is significant as it addresses the need for effective long-term treatment options for this condition in younger populations.

Aurinia Pharmaceuticals Advances Lupus Nephritis Study in Young Patients

Study Overview: Aurinia Pharmaceuticals is conducting a study titled A Double-Blind, Placebo-Controlled, Dose Escalation Study to Assess the Efficacy, Safety and Pharmacokinetics of Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis. The study aims to evaluate the efficacy and safety of voclosporin in achieving renal response in young patients with active lupus nephritis over 24 weeks, highlighting its potential significance in treating this condition.

Aurinia Pharmaceuticals to Present New LUPKYNIS Data at Key Conferences

Aurinia Pharmaceuticals announced that new data on LUPKYNIS (voclosporin) will be presented at the American College of Rheumatology Convergence and the American Society of Nephrology Kidney Week 2025. These presentations, in collaboration with independent investigators, will highlight real-world effectiveness, usage in pediatric patients, and the drug’s distribution and clearance. The findings aim to enhance the medical community’s understanding of voclosporin’s role in treating lupus nephritis, reinforcing Aurinia’s commitment to advancing patient care.

The most recent analyst rating on (AUPH) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Aurinia Pharmaceuticals stock, see the AUPH Stock Forecast page.

Aurinia Pharmaceuticals Reaffirms Confidence in LUPKYNIS After Retraction

Aurinia Pharmaceuticals responded to a retracted LinkedIn post by an FDA official regarding voclosporin, affirming the positive benefit/risk profile of its product LUPKYNIS. The drug, approved by the FDA in January 2021 and for long-term use in April 2024, has shown sustained efficacy and safety in clinical studies, reinforcing Aurinia’s position in the autoimmune treatment market.

The most recent analyst rating on (AUPH) stock is a Buy with a $11.00 price target. To see the full list of analyst forecasts on Aurinia Pharmaceuticals stock, see the AUPH Stock Forecast page.